Terms ending in 2031
Every in-force patent on Celeniv Pte. Ltd.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,200,253 | Method of Producing Erythrocytes In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 8,926,964 | Methods of Generating Natural Killer Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 9,121,007 | Treatment of Bone-Related Cancers Using Placental Stem Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 8,969,315 | Enhancement of Placental Stem Cell Potency Using Modulatory RNA Molecules In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.